The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Medication Preferences & Current Practices for PsA

Medication Preferences & Current Practices for PsA

May 11, 2022 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

ACR CONVERGENCE 2021—The increasing number of targeted and biologic therapies to treat patients with psoriatic arthritis (PsA) has expanded the armamentarium for rheumatology. However, data on medication use in the real-world clinical setting and patient medication preference are limited. Using a cross-sectional survey of patients meeting Classification Criteria for Psoriatic Arthritis (CASPAR) from a single, academic center, researchers ranked patient treatment preferences. Monica Schwartzman, MD, a double-board certified rheumatologist and internal medicine specialist, who is an assistant attending physician at the Hospital for Special Surgery, New York, and a clinical instructor in medicine at Weill Cornell Medical College and New York-Presbyterian Hospital, presented the findings during ACR Convergence 2021.1

You Might Also Like
  • New Data Highlight Effectiveness of Guselkumab for Patients with PsA
  • Risk of IBD in Patients with Psoriasis, PsA & Ankylosing Spondylitis Starting IL-17 Inhibitors
  • The Big Picture: How to Assess Disease Activity in Patients with axSpA & PsA in Clinical Practice
Also By This Author
  • FDA Approves Lesinurad + Allopurinol

The 2018 ACR/National Psoriasis Foundation Guideline for the Treatment of PsA supports using biologic treatments as initial therapy for patients with PsA. Many agents are approved to treat PsA, including:

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE
  • Interleukin (IL) 17 inhibitors, such as brodalumab (Siliq), secukinumab (Cosentyx) and ixekizumab (Taltz);
  • The oral, small-molecule, anti-phosphodiesterase (PDE) 4 agent apremilast (Otezla);
  • Anti-IL-12/23 agents, such as guselkumab (Tremfya), risankizumab (Skyrizi) and ustekinumab (Stelara);
  • Non-steroidal anti-inflammatory drugs (NSAIDs);
  • Glucocorticoids and local glucocorticoid injections for symptomatic treatment;
  • Conventional synthetic disease-modifying anti-rheumatic agents (csDMARDs), such as methotrexate, sulfasalazine, cyclosporine and leflunomide;
  • Anti-tumor necrosis factor alpha (anti-TNF-α) inhibitors, such as adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi/Aria) and infliximab (Remicade/Inflectra/Renflexis);
  • The cytotoxic T lymphocyte-associated antigen-4 immunoglobulin fusion protein (CTLA4-Ig) abatacept (Orencia); and
  • The Janus kinase (JAK) inhibitor tofacitinib (Xeljanz).2,3

For this study, patients with PsA were recruited between June to September 2020. A five-point Likert scale was used to rank patient preferences from not at all important to extremely important.

The Results

One hundred and thirty-seven patients with PsA (29%), with a median age of 60 years old (interquartile range [IQR] 51–70 years), responded to the survey. Their median duration of PsA skin symptoms was 19 years (IQR 10–34), their median duration of joint symptoms was 12 years (IQR 8–21), and their median duration of PsA diagnosis by a physician, from symptom onset, was eight years (IQR 4–17).

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

For 62% of the respondents, an NSAID was the first medication used to treat their PsA. The most commonly used, initial, immunomodulatory medications were anti-TNF-α inhibitors (35%), followed by methotrexate (19%), then by anti-PDE-4 agents (12.4%), other csDMARDs (11.7%), anti-IL17 agents (5.1%) and anti-IL 23 agents (2.9%). At the time the survey was administered in 2020, the most common immunomodulator therapies were TNF-α inhibitors (30%), followed by IL-17 inhibitors (20.4%), methotrexate (10.2%), PDE4 inhibitors (8.8%), other csDMARDs (8.0%), JAK inhibitors (2.2%) and abatacept (1.5%). Twenty-eight percent of patients were not receiving immunomodulatory therapy.

The study found that, after the publication of the 2018 guidelines, a significantly higher percentage of patients’ first medication was an IL-17 inhibitor than prior to 2018. This finding was statistically significant (30% vs. 3.5%; P<0.001). This change was also seen for use of PDE-4 inhibitors, for which first-time use after 2018 was 40% compared with 11.5% (P<0.012) prior to 2018.

Patient medication priorities ranked as extremely important were joint damage prevention (80%), ability to perform activities of daily living (71%), pain management (70%), rheumatologist recommendation (63%) and medication side effects (62%).

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

This survey showed a significant increase in the use of IL-17 inhibitors and PDE4 inhibitors as initial treatment after publication of the 2018 guideline. Patients’ concerns about side effects were also high and should be take into consideration when deciding on PsA management.

With the expanding armamentarium of medications to treat PsA, rheumatologists should ensure they consult with their patients to align their priorities with therapeutic options to ensure continued and lasting use of effective therapy.


Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

  1. Schwartzman M, Abutalib Z, Mandl L. Current medication practices and preferences among patients with psoriatic arthritis (PsA) [abstract 1810]. Arthritis Rheumatol. 2021 Oct; 73(suppl 10).
  2. Al Hammadi A. Psoriatic arthritis medication. Medscape. 2022 Jan 24.
  3. Singh JA, Guyatt G, Ogdie A, et al. 2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. Arthritis Rheumatol. 2019 Jan;71(1):5–32.

Filed Under: ACR Convergence, Conditions, Drug Updates, Meeting Reports Tagged With: ACR Convergence 2021, PsA, PsA Resource Center, Psoriatic Arthritis

You Might Also Like:
  • New Data Highlight Effectiveness of Guselkumab for Patients with PsA
  • Risk of IBD in Patients with Psoriasis, PsA & Ankylosing Spondylitis Starting IL-17 Inhibitors
  • The Big Picture: How to Assess Disease Activity in Patients with axSpA & PsA in Clinical Practice
  • EU Approves Marketing for Ixekizumab in Adults with PsA

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.